Brief: Dimerix And Amicus Therapeutics Announce Exclusive License Agreement For DMX-200 In United States
01/05/2025 24:15
May 1 (Reuters) - Dimerix Ltd DXB.AX: DIMERIX AND AMICUS THERAPEUTICS ANNOUNCE EXCLUSIVE LICENSE AGREEMENT FOR DMX-200 IN UNITED STATES DIMERIX TO RECEIVE US$30 MILLION UPFRONT PAYMENT DIMERIX TO RECEIVE UP TO US$560 MILLION FOR SUCCESS-BASED MILESTONE PAYMENTS Further company coverage: DXB.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Dimerix
See all newsAustralia's Dimerix soars on commercialisation deal with Everest Medicines
Brief: Dimerix Ltd Licenses Dmx200 To Everest For China And Asia Region
Brief: Everest Medicine In Agreement With Dimerix To Develop Commercialize DMX-200 In Greater China, South Korea, And Southeast Asia
Brief: Dimerix Seeks Trading Halt
Brief: Dimerix To Conduct Review Of Action3 Statistical Assumptions